Case File
efta-02464401DOJ Data Set 11OtherEFTA02464401
Date
Unknown
Source
DOJ Data Set 11
Reference
efta-02464401
Pages
1
Persons
0
Integrity
Extracted Text (OCR)
Text extracted via OCR from the original document. May contain errors from the scanning process.
From:
jeffrey E. <[email protected]>
Sent:
Saturday, April 30, 2016 11:44 AM
To:
Jeffrey Epstein
Subject:
REVIEW ALL OTHER APPRAISALS !!!
para 1/ Since the IRS questions 3 and 4 =n the request are the same , we are providing this single response .
2. Empire=selected 15 % as the applicble discount rather than a higher number that m=ghthave been be derived
from the benchmark ranges contai=ed in the Mergerstat Reviews.
3 as contain=d in the orignal valutation. Empire
The range of disc=unt described in these studies for " lack of
control &quo=; was 11.3 to 32.4 percent. and the range of discount for lack of marketab=lity was 21- 27 %. As both
discounts are present in our valua=ion of the BFP ineterest. they would normally be applied sequentially to t=e
valuation, increasing the final discount range to 29.9=- 50.6 %
4 Though the =ergerstat studies inform our decision, in the BFP =ase the actual restrictions are less onerous than
many described in =he studies. requiring us to reduce our total , below even the low end of t=e combined range to only
15 % . The reasons =re as follows
5 THe pri=ary consideration in the reduction of total discount was that in ARicle 3.= of the BFP AGreement . states
that bfp partners may withdraw any po=tion of their capital account at any time. The major asset that woul= likely be
distributed would still carry with it its own disco=nt and well as other retrictions on transfer etc.
In addtio= the timing of the asset transfer exposes the transferee to market risk an= unpredictability. as well as the
requiredment that the General Partner ap=rove any transfer of interest.
= Based on the above it was considered reasonable to
=div dir="ltr">
please note
The information contained =n this communication is confidential, may be attorney-client privileged= may constitute
inside information, and is intended only for the use=of the addressee. It is the property of JEE Unauthorized use,
disclo=ure or copying of this communication or any part thereof is strictly pr=hibited and may be unlawful. If you have
received this communication=in error, please notify us immediately by return e-mail or by e-mail
to=jeevacation@gma=l.com <mailto:[email protected]> , and destroy this communication and all copies thereof,
in=luding all attachments. copyright -all rights reserved
EFTA_R1_01571751
EFTA02464401
Technical Artifacts (3)
View in Artifacts BrowserEmail addresses, URLs, phone numbers, and other technical indicators extracted from this document.
Related Documents (6)
DOJ Data Set 10OtherUnknown
EFTA01682184
186p
OtherUnknown
FEDWIRE PAYMENT DEBIT ADVICE
DOJ EFTA Data Set 10 document EFTA01273102
16p
DOJ Data Set 10OtherUnknown
EFTA01370863
1p
Dept. of JusticeOtherUnknown
Medical Record/Clinical Encounter: DOJ-OGR-00026334
This clinical encounter document from the Bureau of Prisons details a medical evaluation of Jeffrey Epstein on July 12, 2019. It covers his medical history, current complaints, and treatment, including discussions around his triglyceride levels, sleep apnea, and back pain. The document was generated by the treating physician at the Metropolitan Correctional Center in New York.
1p
DOJ Data Set 8CorrespondenceUnknown
EFTA00014087
0p
DOJ Data Set 10OtherUnknown
EFTA01977826
2p
Forum Discussions
This document was digitized, indexed, and cross-referenced with 1,400+ persons in the Epstein files. 100% free, ad-free, and independent.
Annotations powered by Hypothesis. Select any text on this page to annotate or highlight it.